Related Experiment Video

Updated: Jun 10, 2025

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
04:49

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension

Published on: June 14, 2024

619

NT-proBNP Reflects Left Ventricular Hypertrophy Rather than Left Ventricular Dilatation or Systolic Dysfunction in

Constantin Gatterer1, Dietrich Beitzke2, Gere Sunder-Plassmann3

  • 1Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.

Journal of Clinical Medicine
|October 16, 2024
PubMed

Insights

NT-proBNP effectively monitors cardiac involvement in Fabry disease, correlating with left ventricular hypertrophy but not dysfunction. Its prognostic value is highest in hypertrophic stages.

Area of Science:

  • Cardiology
  • Genetics
  • Biomarker Research

Background:

  • Cardiac involvement is a significant challenge in Fabry disease management.
  • Longitudinal monitoring requires integrating cardiac imaging and laboratory biomarkers.
  • N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a potential biomarker for cardiac assessment.

Purpose of the Study:

  • To investigate the association between NT-proBNP levels and cardiac imaging findings in Fabry disease patients.
  • To determine if NT-proBNP reflects hypertrophy or dysfunction in Fabry cardiomyopathy.
  • To assess the role of NT-proBNP in the follow-up of Fabry disease patients.

Main Methods:

  • Prospective, single-centre registry analysis.
  • Inclusion of cardiac MRI and echocardiography data.
  • Analysis of laboratory results, including NT-proBNP levels.

Main Results:

  • NT-proBNP correlated with left ventricular hypertrophy (LVH) parameters (interventricular septal thickness, wall thickness, mass index) in 18/38 Fabry patients with LVH.
  • No significant association between NT-proBNP and LVH parameters was found in patients without LVH.
  • NT-proBNP did not correlate with impaired left or right ventricular ejection fraction or diastolic volume.

Conclusions:

  • NT-proBNP is a key biomarker for cardiac involvement in Fabry disease.
  • In Fabry disease with preserved ejection fraction, NT-proBNP primarily indicates ventricular hypertrophy, not dysfunction.
  • NT-proBNP's prognostic utility is most significant in hypertrophic stages of Fabry cardiomyopathy.

Keywords:
Fabry diseaseNT-proBNPbiomarkercardiac MRIcardiomyopathyechocardiographylysosomal storage disease

More Related Videos

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure06:47

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure

Published on: November 29, 2018

9.6K
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.5K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
61
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
1
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
3
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
4
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1